PF-477736调节血管光滑肌细胞通过Chk1/p53/CD44通路的表型过渡
Yu Lv1, Xia Wang2, Youjie Zeng3
1Department of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China; Department of Orthopaedics, Shanghai Bone Tumor Institute, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
作为Chk1抑制剂的PF-477736有效地逆转了血管光滑肌细胞 (VSMC) 的表型转变,抑制了增殖和迁移. 这项研究揭示了其通过Chk1/p53/CD44通路进行血管改造的治疗潜力.
科学领域:
- 血管生物学 血管生物学
- 细胞信号传递 细胞信号传递
- 药理学 药理学是指药理学的学科.
背景情况:
- 血管光滑肌细胞 (VSMC) 现型转变是血管重塑的核心.
- PF-477736是一种Chk1抑制剂,已知具有抗瘤作用,但其在血管重塑中的作用尚未被探索.
研究的目的:
- 调查PF-477736对VSMC表型转变和血管重塑的影响.
- 阐明潜在的分子机制,包括Chk1/p53/CD44通路.
主要方法:
- 在体外研究中使用人类和老鼠VSMC来建模表型转变,评估增殖和迁移.
- 使用了西斑,MTT,EDU和伤口愈合分析.
- 在体内研究中使用了大鼠动脉气球损伤模型与组织学分析.
主要成果:
- PF-477736抑制了VSMC的表型转变,导致G1/S阶段停止,并减少了增殖和迁移.
- PF-477736抵消了PDGF-bb诱导的p53和CD44表达的变化.
- 在体内,PF-477736在气球损伤模型中显著抑制了血管重塑.
结论:
- 通过抑制VSMC表型过渡,PF-477736显示出抗血管改造效应.
- Chk1/p53/CD44通路对于PF-477736的作用至关重要.
- PF-477736为血管重塑提供了一个新的治疗策略.
更多相关视频
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
07:49Molecular Analysis of Endothelial-mesenchymal Transition Induced by Transforming Growth Factor-β Signaling
Published on: August 3, 2018
相关概念视频
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Regulation of Angiogenesis and Blood Supply
Negative Regulator Molecules
